{
    "key_points": [
        "The World Health Organization (WHO) has issued an emergency use listing (EUL) for COVAXIN\u00ae, developed by Bharat Biotech, for COVID-19 prevention.",
        "COVAXIN\u00ae is the eighth vaccine to receive WHO's EUL for COVID-19.",
        "WHO's EUL is crucial for COVAX vaccine supply and helps countries expedite their regulatory approval processes.",
        "Dr Mari\u00e2ngela Sim\u00e3o emphasized the importance of vaccines and the need to prioritize at-risk groups.",
        "The vaccine's efficacy, safety, and quality were reviewed by the WHO Technical Advisory Group (TAG) and Strategic Advisory Group of Experts on Immunization (SAGE).",
        "COVAXIN\u00ae is formulated from an inactivated SARS-CoV-2 antigen and is suitable for low- and middle-income countries due to easy storage requirements.",
        "SAGE recommended a two-dose regimen of COVAXIN\u00ae, with a dose interval of four weeks, for individuals aged 18 and above.",
        "The vaccine has a 78% efficacy against COVID-19 of any severity, 14 days after the second dose.",
        "Over 120,000 pregnant women in India have been vaccinated with COVAXIN\u00ae with no short-term adverse effects reported.",
        "The EUL process requires the producing company to continue generating data for full licensure and WHO prequalification."
    ],
    "spokespersons": [
        "Dr Mari\u00e2ngela Sim\u00e3o (WHO Assistant-Director General for Access to Medicines and Health Products)"
    ],
    "article_type": "government agency statement",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}